BTIG raised the firm’s price target on Insulet (PODD) to $300 from $270 and keeps a Buy rating on the shares as part of a broader research note updating the firm’s models in select Medical Technology ...

BTIG raised the firm’s price target on Verastem (VSTM) to $20 from $13 and keeps a Buy rating on the shares after the company announced the FDA ...

BTIG notes that Casago has agreed to acquire Neutral-rated Vacasa (VCSA) for $5.02/share in cash with the deal expected to close Q1-Q2 2025.

BTIG analyst Marie Thibault raised the firm’s price target on Boston Scientific (BSX) to $101 from $97 and keeps a Buy rating ...

Shares of Bloom Energy (BE), a firm engaged in stationary fuel cell power generation, were trading in the green on Monday ...

Jonathan Krinsky, BTIG chief market technician, joins 'Closing Bell' to discuss why he's cautious on Apple and the market ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Equities research analysts at BTIG Research assumed coverage on shares of SunCar Technology Group (NASDAQ:SDA – Get Free ...

It isn’t all bad news, said John Krinsky, chief market technician at BTIG, in a Wednesday client note. Tech’s XLK 1.5% fall makes it by far the worst-performing S&P 500 sector and is a concern ...

BTIG analyst Jeet Mukherjee initiated coverage of Arvinas (ARVN) with a Buy rating and $69 price target The company’s lead program, vepdegestrant, is a potent ER degrader for being developed for ...

According to a BTIG strategist, the rally in the index was rejected from the previous support trendline and even though there are still four days left for the Santa Claus rally to deliver gains, there ...